Die Wahl der Chemotherapie unter einer PET-CT-geführten Therapiedeeskalation hat einen signifikanten Einfluss auf die Fertilität und Lebensqualität junger Hodgkin-Patientinnen und Patienten-Reference-Cited by-同舟云学术

Die Wahl der Chemotherapie unter einer PET-CT-geführten Therapiedeeskalation hat einen signifikanten Einfluss auf die Fertilität und Lebensqualität junger Hodgkin-Patientinnen und Patienten

Published:2022-04-22 Issue:8 Volume:198 Page:752-754
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:de
Short-container-title:Strahlenther Onkol

Author:

Guninski Ricarda Stella,Balermpas Panagiotis

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology, Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s00066-022-01946-x.pdf

Reference12 articles.

1. Øvlisen AK et al (2021) Parenthood rates and use of assisted reproductive techniques in younger Hodgkin lymphoma survivors: a Danish population-based study. J Clin Oncol 39:3463–3472

2. Gallamini A et al (2007) Early interim 2‑[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752

3. Carde P et al (2016) Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPP baseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol 34:2028–2036

4. Scorsetti M et al (2020) Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiat Oncol 15:12

5. Casasnovas R‑O et al (2019) PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 20:202–215